<DOC>
	<DOCNO>NCT01235962</DOCNO>
	<brief_summary>This randomized Phase III study evaluate whether pazopanib compare placebo prevent delay recurrence kidney cancer patient moderately high high risk develop recurrence undergo kidney cancer surgery</brief_summary>
	<brief_title>A Study Evaluate Pazopanib Adjuvant Treatment Localized Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Signed write informed consent Diagnosis RCC clearcell predominant clearcell histology Subjects nonmetastatic disease ( M0 ) fulfil follow combination pathologic stag base American Joint Committee Cancer ( AJCC ) TNM stag version 2010 Fuhrman nuclear grading . pT2 , G3 G4 , N0 ; , pT3 , G , N0 ; , pT4 , G , N0 ; , pT , G , N1 Fulfill follow criterion diseasefree status baseline : Had complete gross surgical resection RCC via radical partial nephrectomy use either open laparoscopic technique . Baseline image chest , abdomen pelvis show metastasis residual tumor lesion confirm centrally independent radiologist . Received prior adjuvant neoadjuvant treatment RCC Recovered nephrectomy : surgery related toxicity reduce ≤ grade 1 per NCI Common Terminology Criteria Adverse Events ( CTCAE ) ( Version 4 ) Karnofsky performance scale ( KPS ) ≥ 80 Adequate organ system function History another malignancy . Exception : Subjects another malignancy diseasefree 5 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include , limited : Active peptic ulcer disease Inflammatory bowel disease ( e.g . ulcerative colitis , Crohn 's disease ) , gastrointestinal condition increase risk perforation History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment Active diarrhea grade Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : Malabsorption syndrome Major resection stomach small bowel History human immunodeficiency virus ( HIV ) infection History active hepatitis Presence uncontrolled infection . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease History Class III IV congestive heart failure , define New York Heart Association Classification Congestive Heart Failure History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Corrected QT interval ( QTc ) &gt; 480 millisecond ( msec ) Poorly control hypertension , define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . Blood pressure ( BP ) must reassess two occasion separate minimum 1 hour ; occasion , mean ( 3 reading ) SBP / DBP value BP assessment must &lt; 140/90 mmHg order subject eligible study ( see Section 7.6.2 instruction blood pressure measurement obtain mean blood pressure value ) . Evidence active bleeding bleed diathesis Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure Unable unwilling discontinue use prohibit medication least 14 day five halflives drug ( whichever longer ) prior first dose study treatment duration study . Concurrent therapy give treat cancer include treatment investigational agent concurrent participation another clinical trial involve anticancer investigational drug . Administration investigational drug within 30 day 5 halflives , whichever longer , precede first dose study treatment . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib excipients opinion investigator contraindicate participation . Prior current use systemic antiVEGF inhibitor , cytokine ( e.g . interferon , interleukin 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>anti-angiogenic agent</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>pazopanib</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>VEGFR inhibitor</keyword>
</DOC>